Edwards Lifesciences Corporation
EW Healthcare Medical - Devices NYSE
$84.12
+$0.47 (+0.56%)
Open: $83.38 | High: $84.39 | Low: $83.25 | Prev Close: $83.66
Market Cap: $49.39B
Volume: 751K | Avg: 4.0M
Last updated: January 26, 2026 at 06:02 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 545
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 36.89 |
| P/B Ratio | 4.82 |
| P/S Ratio | 8.39 |
| EPS | $2.28 |
| Beta | 0.96 |
| Shares Outstanding | 587.10M |
| 52-Week High | $87.89 |
| 52-Week Low | $65.94 |
| SMA 50 | $85.01 |
| SMA 200 | $78.93 |
| Next Earnings | February 10, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 78.2% |
| Operating Margin | 26.6% |
| Net Margin | 23.2% |
| ROE | 13.4% |
| ROA | 10.3% |
| Debt/Equity | 0.07 |
| Current Ratio | 4.00 |
| Quick Ratio | 3.29 |
Balance Sheet
| Total Assets | $13.06B |
| Total Liabilities | $2.99B |
| Total Equity | $10.00B |
|
|
|
| Cash | $3.05B |
| Total Debt | $700.00M |
| Net Debt | $-2,345,200,000 |
Income Statement
| Revenue | $5.44B |
| Gross Profit | $4.32B |
| Operating Income | $1.38B |
| Net Income | $4.17B |
|
|
|
| EBITDA | $1.72B |
| Revenue/Share | $10.06 |
Cash Flow
| Operating CF | $542.30M |
| CapEx | $252.40M |
| Free Cash Flow | $289.90M |
|
|
|
| Book Value/Share | $17.45 |
| Tangible Book/Share | $12.49 |
| Equity/Share | $17.45 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | EW | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 36.89 | 35.25 | 66% |
| P/B Ratio | 4.82 | 0.17 | 54% |
| ROE (%) | 13.35% | 14.19% | 46% |
| Net Margin (%) | 23.19% | 9.35% | 76% |
| Stock Score | 545 | 467.0 | 76% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EW | $84.12 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the EW stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| EW | Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors | Positive | marketbeat.com | Read More |
| EW | Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of “Moderate Buy” by Analysts | Neutral | defenseworld.net | Read More |
| EW | Bank Hapoalim BM Sells 11,250 Shares of Edwards Lifesciences Corporation $EW | Neutral | defenseworld.net | Read More |
| EW | Wedgewood Partners: Q4 2025 Top Performers And Detractors | Neutral | seekingalpha.com | Read More |
| EW | Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? | Neutral | zacks.com | Read More |
Recent Insider Trading
No recent insider trading data available for EW
Company Information
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| CEO | Bernard J. Zovighian |
| Employees | 15800 |
| Country | US |
| IPO Date | 2000-03-27 |
| Exchange | NYSE |
| Website | https://www.edwards.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category